Key result
CRT fails to restore reduced regulatory T cell levels in chronic HF.
Why the study?
The impact of cardiac resynchronization therapy on the inflammatory immune response and T cells in chronic heart failure remains controversial.
Does cardiac resynchronization therapy improve T cell subpopulations and inflammatory response in patients with advanced heart failure?
Observational (n=50)
No
Does cardiac resynchronization therapy improve T cell subpopulations and inflammatory response in patients with advanced heart failure?
Answers are grounded in this paper and cite their sources.
Cardiac resynchronization therapy does not restore the reduced levels of regulatory T cells in chronic heart failure patients, suggesting that the underlying inflammatory condition continues to evolve despite reverse remodeling.
Background T cells have been implicated in the development and progression of inflammatory processes in chronic heart failure (CHF). Cardiac resynchronization therapy (CRT) has beneficial effects on symptoms and cardiac remodeling in CHF. However, its impact on the inflammatory immune response remains controversial. We aimed to study the impact of CRT on T cells in heart failure (HF) patients. Methods Thirty-nine HF patients were evaluated before CRT (T0) and six months later (T6). Quantification of T cells, their subsets, and their functional characterization, after in vitro stimulation, were evaluated by flow cytometry. Results T regulatory (Treg) cells were decreased in CHF patients (healthy group (HG): 1.08 ± 0.50 versus (heart failure patients (HFP)-T0: 0.69 ± 0.40, P = 0.022) and remaining diminished after CRT (HFP-T6: 0.61 ± 0.29, P = 0.003). Responders (R) to CRT presented a higher frequency of T cytotoxic (Tc) cells producing IL-2 at T0 compared with non-responders (NR) (R: 36.52 ± 12.55 versus NR: 24.71 ± 11.66, P = 0.006). After CRT, HF patients presented a higher percentage of Tc cells expressing TNF-α and IFN-γ (HG: 44.50 ± 16.62 versus R: 61.47 ± 20.54, P = 0.014; and HG: 40.62 ± 15.36 versus R: 52.39 ± 18.66, P = 0.049, respectively). Conclusion The dynamic of different functional T cell subpopulations is significantly altered in CHF, which results in an exacerbated pro-inflammatory response. Even after CRT, it seems that the inflammatory condition underlying CHF continues to evolve with the progression of the disease. This could be due, at least in part, to the inability to restore Treg cells levels. Trial registration : Observational and prospective study with no trial registration.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2023) conducted an observational in Chronic heart failure (n=50). Cardiac resynchronization therapy (CRT) vs. Healthy control group was evaluated on Frequency of regulatory T (Treg) cells (%) (p=0.003). Cardiac resynchronization therapy did not restore the significantly reduced levels of regulatory T cells in patients with chronic heart failure after 6 months of treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: